Abstract
Background: Although carcinoembryonic antigen (CEA) is the most frequently used marker for colon cancer, it is elevated in only 70% of patients with advanced disease and in even fewer patients with earlier stages of disease. We previously identified a 90-kDa glycoprotein, TA90, which is present in serum in the form of circulating immune complexes. TA90 is found in a variety of solid neoplasms but rarely in healthy controls (3.2%). We hypothesized that this new tumor-associated antigen may be a useful marker for colon cancer.
Methods: Serum samples from 59 patients with known colon adenocarcinoma were analyzed for the presence of CEA and TA90. Fifty-one (86%) patients had distant metastases; the remaining patients had clinically localized primary colon cancer. A murine monoclonal antibody-based enzyme-linked immunosorbent assay was used to measure concentrations of TA90-specific circulating immune complexes (TA90-IC). A positive value was defined as an optical density of more than 0.410 at 405 nm. Forty-seven (80%) of the 59 patients had serum samples for TA90 and CEA drawn at the same time.
Results: TA90-IC concentrations were elevated more frequently than CEA concentrations (82.9% vs. 70.2%; P 5.134). The combination of both markers identified more patients with colon carcinoma than did either marker alone (93.6%; P,.001).
Conclusions: Concomitant use of TA90-IC and CEA identified 93.6% of patients with advanced colon cancer. The role of TA90-IC in screening and monitoring progression of earlier disease deserves further investigation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Ransohoff DF, Lang CA. Screening for colorectal cancer with fecal occult blood test: a background paper. Ann Intern Med 1997;126:811–22.
Atkin WS, Hart A, Edwards R, et al. Uptake, yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening. Gut 1998;42:560–5.
Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991;5:344–66.
Moertel CG, Fleming TR, McDonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of CEA test for monitoring patients with resected colon cancer. JAMA 1993;270:943–7.
Carpelan-Holmstrom MA, Haglund CH, Roberts PJ. Differences in serum tumor markers between colon and rectal cancer. Dis Colon Rectum 1996;39:799–805.
Von Kleist S, Hesse Y, Kananeeh H. Comparative evaluation of four tumor markers, CA242, CA19/9, TPA and CEA in carcinomas of the colon. Anticancer Res 1996;16:2325–2332.
Carpelan-Holmstrom MA, Haglund C, Jarvinen HJ, Roberts PJ. Serum CA242, and CEA detect different patients with recurrent colorectal cancer. Anticancer Res 1996;16:981–6.
Nilsson O, Johansson C, Glimelius B, et al. Sensitivity and specificity of CA242 in gastro-intestinal cancer: a comparison with CEA, CA50 and CA19/9. Br J Cancer 1992;65:215–21.
Euhus DM, Gupta RK, Morton DL. Characterization of 90–100 kDa tumor-associated antigen in the sera of melanoma patients. Int J Cancer 1990;45:1065–70.
Gupta RK, Morton DL. Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated antigen-specific immune complexes in cancer patients. J Clin Lab Anal 1992;6:329–36.
Wong JH, Xu SH, Gupta RK, Morton DL. Tumor-associated antigen immune complexes, a potential marker for recurrent melanoma. Arch Surg 1990;125:187–91.
Hsueh EC, Gupta RK, Qi K, Yee R, Leopoldo ZC, Morton DL. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma. Cancer J Sci Am 1997;3:364–70.
Jones RC, Kelley M, Gupta RK, et al. Immune response to PMCV in AJCC stage III melanoma: an immunologic survival model. Ann Surg Oncol 1996;3:437–45.
Kelley MC, Jones RC, Gupta RK, et al. Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early-stage melanoma. Cancer 1998;83:1355–61.
Chester SJ, Maimonis P, Meitner PA, Vezeridis MP. An analysis of immuno-complexes for the detection of the early stages of colon cancer. Cancer 1990;65:1338–44.
Fleming ID, Cooper JS, Henson DE, et al, eds. AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1998.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Habal, N., Gupta, R.K., Bilchik, A.J. et al. TA90-IC, A New Marker for Advanced Colon Cancer. Ann Surg Oncol 7, 352–356 (2000). https://doi.org/10.1007/s10434-000-0352-y
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-000-0352-y